
Warm nights and ill premature babies?
A study from Hanover investigates the spread of Klebsiella in the neonatal intensive care unit.

TWINCORE was founded in 2008 by the Helmholtz Centre for Infection Research and the Hannover Medical School. We combine the expertise of medical professionals and scientists from a wide range of disciplines to find answers to the pressing questions in infection research. Our focus: translational research – the bridge between basic science and clinical application.
This year's TWINCORE Symposium
Pathways to infection resilience
will take place on 3 - 4 September.

A study from Hanover investigates the spread of Klebsiella in the neonatal intensive care unit.

TWINCORE researchers investigate gene activity in host cells

Diverse Origins – One Goal
We conduct translational infection research to improve the prevention, diagnosis and treatment of infectious diseases in humans. We focus on three areas that characterize our research work. Find out here how we proceed and what results we achieve.
Under the leadership of our best scientists, various labs are working on different projects within our research topics.
Szafrański S, Joshi A, Steglich M, Yang I, Qu T, Behrens W, Muthukumarasamy U, Melidis D, Schaefer-Dreyer P, Grischke J, Hegermann J, Nejdl W, Häussler S, Stiesch M
Sidarous L, Ibrahim M, Elhadidy M, Abouelfetouh A, Saif N, Aboelnaga N, Shehat M, Youssef M, Badr E
Moch J, Kappes J, Jauregui R, Schmaus H, Dietrich M, Thies D, Roesner L, Werfel T, Förster R, von Witzendorff D, Debarry J, Winkelmann M, Oberthür S, Clausen J, Gogol M, Cornberg M, Kraft A, Niehaus C
The project investigates how HCMV is recognized by the immune system and which mechanisms the virus uses to camouflage itself. The aim is to understand the immune reactions and develop therapies for severely affected patients.
The project investigates immune reactions in viral hepatitis, in particular the role of hepatocytes and myeloid cells. The aim is to understand immune processes in the liver and to develop diagnostic approaches for the clinic.
Older people are at high risk of a poor immune response to the flu vaccine. Together with partners, we are looking for biomarkers and risk factors for this inadequate response and are investigating ways to improve the vaccination response.
Monoclonal antibodies are transforming modern medicine. At Helmholtz Infection Medicine at MHH, bringing together TWINCORE and CiiM, advanced technologies and AI drive the development of next-generation human antibodies against major infectious diseases.
Ralf Meister, Bishop of the Evangelical-Lutheran Church of Hanover
“Participation and Resilience at the Interface between Science and Society”
Moritz Gaidt, IMP - Research Institute of Molecular Pathology, Vienna
Marylyn M. Addo - UKE Hamburg

